Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp itric oxide (NO), a potent vasodilator, regulates systemic blood pressure (BP) and local blood flow. A deficiency of NO can lead to vasoconstriction and cause diseases including hypertension and chronic kidney disease (CKD). 1-3 Reduced l-arginine (ARG) bioavailability and increased asymmetric dimethylarginine (ADMA) both contribute to NO deficiency. 3 ARG is a substrate for the synthesis of NO and this constitutes the rationale for manipulating ARG metabolism as a therapeutic approach for kidney disease and hypertension. 4 Because ARG is involved in multiple metabolic pathways, 5 there are discrepant findings in the literature according to the plasma level of ARG in patients with CKD and hypertension. 6-8 ARG can be metabolized by arginase to generate ornithine, which can be further converted to l-citrulline (CIT). In contrast, the body can use CIT to make ARG via the argininosuccinate (AS) pathway involving AS synthetase and lyase. 9 In human and experimental CKD, renal CIT uptake is diminished, the amount of CIT converted to ARG in the kidney is reduced, and plasma CIT levels and turnover are elevated. 6-8,10,11 We and others demonstrated that reduced renal ARG availability precedes hypertension in the young spontaneously hypertensive rat (SHR). 12, 13 We also found that restoration of renal ARG availability is associated with lowering BP in young SHR. 12 Renal ARG level, however, is not correlated with the levels of ARG and dimethylarginine in the plasma. 14 These findings suggest that decreased renal ARG level could develop in early CKD causing BP abnormalities, which might be predicted by plasma CIT level and CIT-to-ARG ratio.
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isomer, symmetric dimethylarginine (SDMA), cannot directly inhibit NOS and is excreted by the kidney into the urine only. Thus the plasma ADMA-to-SDMA ratio has been proposed to reflect DDAH activity. Although plasma levels of ADMA and SDMA are both increased in patients with hypertension and CKD, 18, 19 little attention has been paid to understand the role of their levels and combined ratios in the development of hypertension in CKD. Because CIT, ARG, ADMA, and SDMA are all tightly linked to the NO pathway (Figure 1) , we assume that simultaneous analysis of their combined ratios may provide more information to reflect NO homeostasis. Pre-hypertension and hypertension are prevalent complications in children with CKD. 20 Even in early CKD, approximately 50% of children have BP abnormalities, which are associated with poor cardiovascular outcome. 21 24 -h ambulatory BP monitoring (ABPM) has proven to be a superior predictor of cardiovascular outcome when compared to clinic BP measurement. Our recent report showed that plasma ARG-to-ADMA ratio and ADMA-to-SDMA ratio are better markers than each individual parameter (ARG, ADMA, and SDMA) to predict hypertension in young SHR. 14 In addition, we hypothesized that plasma CIT-to-ARG ratio reflects renal ARG availability, which may relate to BP abnormalities in children with CKD. Thus the aim of this study was to elucidate whether the ARG-to-ADMA ratio, ADMA-to-SDMA ratio, and CITto-ARG ratio in the plasma are superior to each individual parameter in relating to BP abnormalities on ABPM in children with early CKD.
Methods

Subjects
Participants were recruited from children and adolescents referred to Kaohsiung Chang Gung Memorial Hospital for further CKD evaluation. Informed consent was obtained; the research protocol was approved by the Chang Gung Memorial Hospital Institutional Review Board, and followed the 1964 Declaration of Helsinki. In order to gain better insight on BP abnormalities among children with early stages of CKD, 44 children aged 3-18 years confirmed with CKD stages 1-3 at the pediatric nephrology clinic were examined. All children were assigned to CKD stage 1 (ie, normal estimated glomerular filtration rate [eGFR] ≥90 ml · min -1 · 1.73 m -2 ) or CKD stages 2-3 (ie, abnormal eGFR 30-90 ml · min -1 · 1.73 m -2 ) according to eGFR. The CKD staging was defined according to the K/DOQI guideline. 22 eGFR was calculated by the Schwartz formula on the basis of body height and creatinine (Cr) level. 23 Cr level in plasma was measured using the Jaffe reaction. Stage 1 CKD was defined as eGFR ≥90 ml · min -1 · 1.73 m -2 associated with the following high-risk groups: solitary kidney, renal hypoplasia/dysplasia, obstructive nephropathy, bilateral grade IV-V vesico-ureteral reflux, neurogenic bladder, bladder outlet obstruction, steroid-resistant nephrotic syndrome plus proteinuria (>1 g/day), and systemic lupus erythematosus. 24 Both groups of patients were followed according to the study protocol for clinical and biomedical measures. The exclusion criteria included current pregnancy, renal transplantation, inability to complete major data collection procedures (eg, blood sampling), and history of congenital heart disease.
ABPM
In this study 3 consecutive seated BP readings were recorded and clinical BP was the mean of the last 2 readings. The 24-h ABPM data were collected using an Oscar II monitoring device (SunTech Medical, Morrisville, NC, USA). A single experienced nurse specialist applied the monitor. The ABPM was set to record the BP and pulse rate at 20-min intervals over 24 h. Patient diary cards were used to document each subject's daily activities and times of sleep and waking. BP readings >25% of any individual recordings were likely erroneous and excluded from analysis. Abnormal ABPM profile was determined based on (1) average daytime, average night-time, or average 24-h BP exceeding 95th percentile stratified by gender and height using ABPM reference data; 25 (2) 24-h systolic or diastolic BP load ≥25%; and (3) nocturnal decrease of BP by <10% compared with average daytime BP. 25, 26 Because Figure 1 . Scheme of synthesis and metabolism of CIT, ARG, ADMA, and SDMA. ARG has multiple metabolic fates, including metabolism by NOS and arginase. CIT can be generated by NOS, DDAH, and OCT. The only route of CIT metabolism is via the ASS/ ASL pathway. Both ADMA and SDMA come from methylated ARG by PRMT, but only ADMA can be metabolized by DDAH. ADMA, asymmetric dimethylarginine; ARG, l-arginine; ASL, argininosuccinate lyase; ASS, argininosuccinate synthetase; CIT, l-citrulline; DDAH, dimethylarginine dimethylaminohydrolase; DMA, dimethylamine; NOS, nitric oxide synthase; OCT, ornithine carbamoyltransferase; PRMT, protein arginine methyltransferase; SDMA, symmetric dimethylarginine. CAR and BP Abnormalities in Pediatric CKD ARG, nitrate, and nitrite levels can be affected by food intake, we collected blood samples after overnight fast. We also suggested that families avoid giving their children foods rich in ARG (eg, peanut and gelatin), CIT (eg, watermelon), nitrates (eg, sausage), and nitrites (eg, green leafy vegetables) for 1 week before blood sampling, but complete food restriction was not practical in this age group.
Biochemistry and High-Performance Liquid Chromatography
Fasting plasma specimens were aliquoted and stored at -80°C until analysis. Uric acid, glucose, total cholesterol, triglyceride, calcium, phosphate, and hematocrit were measured by standard laboratory assays. Plasma levels of nitrite (NO2 -) and NOx (NO2 -+NO3 -) were measured by the Griess reaction as previously described. 27 CIT, ARG, ADMA, and SDMA in plasma were measured using high-performance liquid chromatography (HP series 1100, Agilent Technologies) with the o-phthaldialdehyde 3-mercaptopropionic acid (OPA-3MPA) derivatization reagent as described previously. 12 The standards contained ARG, CIT, ADMA, and SDMA at 1-100 μmol/L, 1-100 μmol/L, 0.5-5 μmol/L, and 0.5-5 μmol/L, respectively. The recovery rate was approximately 85-105%. The inter-assay coefficient of variation (CV) for CIT and ADMA was 7.5% and 12.5%, whereas the intra-assay CV was 4.6% and 4.9%, respectively.
Statistical Analysis
Continuous data are presented as mean ± SD. The independent t-test or the Mann-Whitney U-test was used to test differences in variables between children with CKD stage 1 and those with CKD stages 2-3. The association between variables was examined using the Pearson correlation coefficient. Chi-squared analysis was used to compare frequency (proportion, %) of abnormal ABPM parameters between groups with biomarkers above and below the median. P<0.05 was considered statistical significant. All analysis was done using SPSS 14.0 (SPSS, Chicago, IL, USA).
Results
We enrolled a total of 44 patients (M=28, F=16) with stages 1-3 CKD, which included 21 cases of congenital anomaly of genitourinary tract (48%), 14 cases of renal parenchymal disease (32%), 7 cases of systemic disease (16%), 1 case of genetic disorder (2%), and 1 case of renal vascular disease (2%). As shown in Table 1 , children with CKD stage 2-3 had higher Cr but lower eGFR compared to those with CKD stage 1. Approximately 20.4% (9/44) of patients were diagnosed as having hypertension on clinical BP measurement. There was no statistical difference in patients with hypertension between the 2 groups. Except for uric acid level, there were no significant differences between the groups in terms of clinical characteristics, BP, or CKD-related biochemistry.
Unlike clinical BP measurement, we found up to 77.3% (34/44) of children with CKD had at least 1 of the BP abnormalities on ABPM in this study. ABPM identified 6 patients (13.6%) with 24-h hypertension, 6 patients (13.6%) with daytime hypertension, 13 patients (29.5%) with night-time hypertension, 23 patients (52.3%) with increased systolic BP load, 7 patients (15.9%) with increased diastolic BP load, and 22 patients (50%) with nocturnal BP non-dipping.
As shown in Table 2 , plasma CIT and CIT-to-ARG ratio were higher in children with CKD stages 2-3 than in those with CKD stage 1. Plasma levels of ARG, ADMA, and SDMA and their combined ratios, however, were not different between children with different stages of CKD. Similarly, the plasma nitrite levels were not different between children with different stages of CKD (CKD stage 1, 0.52±0.65 μmol/L vs. CKD stages 2-3, 0.92±0.68 μmol/L). There were also no differences in plasma NOx (NO2 Table 3 lists the correlations between NOx and CIT/ARG/ADMA/SDMA profiles. Both nitrite and NOx were positively correlated with CIT and CIT-to-ARG ratio in the plasma. There was a mild positive correlation between nitrite level and plasma ARG-to-ADMA ratio.
Next, plasma CIT level was significantly higher in children with nocturnal BP non-dipping and abnormal ABPM profile than those with normal profile (Table 4) . Plasma CIT-to-ARG ratio was significantly increased in children with abnormal AAR, ARG-to-ADMA ratio; ADMA, asymmetric dimethylarginine; ARG, l-arginine; ASR, ADMA-to-SDMA ratio; CAR, CIT-to-ARG ratio; CIT, l-citrulline; CKD, chronic kidney disease; SDMA, symmetric dimethylarginine. LIN YJ et al.
ABPM profile, including nocturnal hypertension, increased diastolic BP load, and non-night dipping. Both plasma CIT level and CIT-to-ARG ratio, however, were not different in children with early CKD stratified by abnormal vs. normal clinical BP. We also found that plasma NOx was significantly increased in children with increased diastolic BP load. In addition, the frequency of each abnormal ABPM parameter was not different between children with different stages of CKD (Figure 2A) . Nevertheless, children with CKD with an elevated plasma CITto-ARG ratio (above the median) were more likely to have increased systolic and diastolic BP loads, nocturnal BP non-dipping, and abnormal ABPM profile ( Figure 2B ). This tendency, however, was not observed for CIT or ARG individually. Using data pooled from all subjects (CKD stages 1-3), correlations of eGFR with NOx, CIT, ARG, ADMA, SDMA and their combined ratios (ARG-to-ADMA ratio, ADMA-to-SDMA ratio, and CIT-to-ARG ratio) were not significant. Similarly, systolic and diastolic BP loads were not correlated with these parameters except for CIT-to-ARG ratio, which had a slight correlation with diastolic BP load (r=0.335, P=0.026).
Discussion
In this study of children with early CKD, we found a remarkably high prevalence of increased BP load, non-dipping, and nocturnal hypertension. We found that approximately 77.3% of children with early CKD had BP abnormalities on ABPM, which is consistent with previous studies that indicated that hypertension is a prevalent comorbidity in children with CKD but which may be often under-diagnosed. 20, 21 Importantly, high CIT level and CIT-to-ARG ratio in the plasma were associated with BP abnormalities on ABPM in children with early CKD.
Elevated plasma CIT was found in patients and rats with advanced CKD, indicating reduced CIT uptake and ARG Table 2 . Tables 1-3 . CAR and BP Abnormalities in Pediatric CKD production in the damaged kidney. 6,11 Because the metabolism of CIT is primarily regulated by the intestine (synthesis) and the kidney (degradation), plasma CIT level can be used as a marker of bowel or renal dysfunction. 28 We found that children with CKD stages 2-3 have higher plasma CIT level and CIT-to-ARG ratio compared to those with CKD stage 1, but plasma ARG level was not different between the 2 groups. These findings suggest that in early CKD the kidney has a compensatory increase in CIT synthesis and/or uptake, resulting in increased renal ARG production to maintain a steady level of ARG in the plasma. If these compensatory mechanisms fail, renal ARG deficiency may develop, leading to hypertension. It is in line with previous observations that renal NO deficiency due to impaired CIT-ARG conversion precedes hypertension, and that restoration of renal ARG availability is associated with lowering BP in young SHR. 12, 13 Importantly, children with early CKD with high CIT have abnormal ABPM profile. Combined analysis of plasma CIT and ARG to generate a CIT-to-ARG ratio improved the significance for predicting BP abnormalities on ABPM in chil- dren with early CKD. Although children with CKD stages 2-3 have increased plasma CIT-to-ARG ratio, the high frequency of abnormal ABPM profile is associated with high CITto-ARG ratio but not high CKD stage. Similarly, data from the ESCAPE study showed that children with stages 2-4 CKD are prone to have nocturnal BP non-dipping, which is not associated with GFR. 29 Yet with strict BP control in these children, progression of CKD can be delayed. 30 The present data highlighted that BP abnormalities, especially at night, develop early in children with CKD, which is related to plasma CIT-to-ARG ratio. Thus early detection and aggressive management targeting the CIT-ARG-NO pathway might be a promising strategy to treat hypertension in children with early CKD. Given that ABPM has been shown to be superior in predicting either target organ damage or comorbidity, 31, 32 and ABPM has been used in the evaluation of the pharmacologically anti-hypertensive effects, we must determine whether the CIT-to-ARG ratio is beneficial in predicting progression of CKD, cardiovascular outcomes, and therapeutic response in future studies.
Although most evidence supports NO deficiency in CKD and hypertension, 1-3 some reports noted that NO synthesis was increased in patients with CKD. 7 In the present study, nitrite and NOx levels were not different between children with CKD stage 1 and those with CKD stages 2-3. Interestingly, we found that high NOx is related to high diastolic BP load and tends to high clinical BP. The present findings suggest that even as CKD is characterized by reduced NO synthesis in the kidney, 3 a compensatory increase of total NO production might be expected instead. We found that both nitrite and NOx were positively related to CIT and CIT-to-ARG ratio in the plasma. Thus high CIT-to-ARG ratio in early CKD children with BP abnormalities might reflect high conversion rate of ARG to CIT to generate NO as a compensatory response to elevation of BP.
So far, NOx remains a useful index of NO generation, although it cannot represent biologically active NO. 33 Instead, it is possible that NOx levels increase while bioactivity of NO decreases, or vice versa. Given that apparent variation in methodologies used to evaluate NO synthesis in humans exists, 34 there is a need to develop an ideal measure of bioactive NO in vivo in order to unravel these mysteries in future studies.
CIT supplementation improves ARG availability and enhances NO production more than ARG itself because it bypasses splanchnic extraction, it is not a substrate for arginase, and it avoids the harmful effects of an excessive ARG supply. 28, 35 Thus supplemental CIT has therapeutic use as a treatment of cardiovascular disease involving NO deficiency, including hypertension. 35-37 Taking into consideration that high plasma CIT is associated with hypertension in children with early CKD and that this high ratio relates to high NOx level, the question of whether CIT supplementation is beneficial to treat hypertension in children with early CKD needs further evaluation. There are potentially several mechanisms involved in the development of hypertension. In addition to NO deficiency, oxidative stress and inflammation may contribute to endothelial dysfunction, 1,38,39 an early event of cardiovascular disease. Given that endothelial function can be protected by CIT or ARG supplementation, 5,9,35,36 it is possible that the CIT-ARG pathway may modulate oxidative stress and inflammation to influence BP.
Although a previous report demonstrated that plasma SDMA level correlated positively with BP load in children with early CKD, 40 such findings are not supported by the present data. The present results, however, are in good agreement with that previous study in that there was no association between BP abnormalities and ARG, ADMA, ARG-to-ADMA ratio, or ADMA-to-SDMA ratio. 40 Of significant interest is that the correlation between BP abnormalities and ARG-to-ADMA ratio or ADMA-to-SDMA ratio was not significant, which is inconsistent with our previous findings showing that plasma ARGto-ADMA ratio and ADMA-to-SDMA ratio are superior markers to predict hypertension in young SHR. 14 Given the fact that SHR is not a CKD-induced hypertension model, additional studies are needed across all insults of hypertension regarding the relationship between these markers and BP abnormalities in children.
This study has several limitations. First, statistical comparisons were performed in a small cohort of children and adolescents with early CKD. A larger sample size is required to detect the true differences. Next, we did not recruit non-CKD controls because we examined the difference of clinical and biomedical features between 2 levels of renal function. That is, in the present study children with CKD stage 1 served as the controls. We found that there was no difference in each citrulline-related parameter between healthy controls and children with CKD stage 1 (data not shown). In addition, we used ABPM reference from the German group. 26 Ethnic differences should be considered, 41 even though 1 study found no difference in ABPM between Taiwanese children and German children in the age group 6-14 years of age. 42 Plasma ARG, CIT, and dimethylarginine measurements in patients are not yet performed on a routine basis and thus there is still a lack of simultaneous measurements and of their combined ratios in numerous clinical studies. To date, there is no clear cut-off for ARG-to-ADMA ratio, ADMA-to-SDMA ratio, and CIT-to-ARG ratio to define the limit between healthy subjects and children with different diseases, including hypertension and CKD. Last, measurement of biologically active NO instead of plasma NOx might provide more information about in vivo NO generation in early CKD.
Conclusion
Hypertension was highly prevalent in children and adolescents with early CKD. BP abnormalities on ABPM including nocturnal hypertension, increased diastolic BP load, and nocturnal BP non-dipping were associated with increased plasma CITto-ARG ratio, which suggested the impact of the CIT-ARG-NO pathway on CKD-related hypertension. It is imperative to detect BP abnormalities early and to translate the study findings into an effective therapeutic approach to improve cardiovascular outcome in children with CKD.
